UCLA Develops Off-the-Shelf CAR-NKT Cell Therapy for Ovarian Cancer Treatment
核心洞察
UCLA researchers have developed a novel CAR-NKT cell therapy (搜索) that successfully killed ovarian cancer (搜索) cells in all 35 patient-derived tumor samples tested, including both newly diagnosed and chemotherapy-resistant cases.
The off-the-shelf immunotherapy uses invariant natural killer T cells (搜索) that can target dozens of molecular markers simultaneously, making it extremely difficult for cancer to develop resistance compared to conventional CAR-T therapies.
The therapy addresses manufacturing bottlenecks by using donated blood stem cells to mass-produce treatments at approximately $5,000 per dose, compared to hundreds of thousands of dollars for personalized CAR-T therapies.
UCLA researchers have achieved a significant breakthrough in ovarian cancer (搜索) treatment with the development of an innovative CAR-NKT cell therapy (搜索) that demonstrated 100% efficacy in preclinical testing across 35 patient-derived tumor samples. The therapy, detailed in the journal Med, represents over a decade of research collaboration between immunologist Dr. Lili Yang and gynecologic oncologist Dr. Sanaz Memarzadeh.
Revolutionary Multi-Target Approach
The CAR-NKT cell therapy (搜索) harnesses invariant natural killer T cells (搜索) equipped with chimeric antigen receptors, offering a fundamentally different approach to cancer immunotherapy. Unlike conventional CAR-T cells that recognize only one target on cancer cells, these engineered CAR-NKT cells can identify dozens of molecular markers simultaneously.
"Cancer is like a moving target because it's constantly changing and adapting," explained first author Dr. Yanruide (Charlie) Li, a postdoctoral scholar in the UCLA Broad Stem Cell Research Center (搜索) Training Program. "The best strategy is to attack from multiple sites simultaneously."
This multi-target capability addresses a critical limitation in current ovarian cancer (搜索) treatment, where more than 80% of patients experience cancer recurrence that becomes increasingly resistant to conventional therapies. The comprehensive attack strategy prevents tumors from developing their usual resistance mechanisms.
Enhanced Tumor Penetration and Dual Action
CAR-NKT cells demonstrate superior ability to penetrate the protective barriers that shield ovarian tumors from conventional CAR-T cells. The therapy operates through a dual mechanism, directly killing cancer cells while simultaneously eliminating immunosuppressive cells that protect tumors.
"These cells are special because they can directly kill cancer cells and also take down the immunosuppressive cells that protect the tumor," said Yang, who is also a member of the UCLA Health Jonsson Comprehensive Cancer Center (搜索).
All tested ovarian cancer (搜索) samples showed high expression of activating natural killer receptor ligands (搜索), indicating strong potential for targeting these receptors in ovarian tumors.
Off-the-Shelf Manufacturing Revolution
The therapy addresses significant manufacturing and cost barriers associated with current cellular immunotherapies. Traditional CAR-T treatments require collecting individual patients' immune cells, modifying them in specialized laboratories, and returning them to patients—a process taking several weeks and costing hundreds of thousands of dollars.
Yang's team developed a scalable strategy to mass-produce CAR-NKT cells from donated blood stem cells. Because NKT cells naturally work with any immune system, patient-specific production is unnecessary. A single donation could yield enough cells for thousands of treatments, reducing costs to approximately $5,000 per dose.
"Our vision is to make CAR-NKT cells available as an off-the-shelf therapy at hospitals in the U.S. and worldwide," Yang stated. "Instead of weeks-long delays for custom manufacturing, doctors could prescribe and access these cells immediately when patients need them most."
Superior Safety Profile
Beyond efficacy advantages, CAR-NKT cells demonstrate improved safety characteristics compared to conventional CAR-T therapies. The research team reported that CAR-NKT cells exhibit reduced cytokine release syndrome, do not induce graft-versus-host disease, and resist host immune-cell-mediated rejection.
Clinical Translation and Broader Applications
With preclinical studies complete, the research team is preparing to submit an FDA application to begin clinical trials. The therapy's initial focus on ovarian cancer (搜索)—the leading cause of death among women with gynecological cancers—could expand to other solid tumors sharing similar defensive mechanisms.
"Our preclinical testing across different cancer types is showing encouraging outcomes," Yang explained. The team plans to explore applications in lung cancer (搜索), brain cancer (搜索), and other solid tumors where conventional CAR-T therapies have shown limited success.
"Combating this high rate of recurrence in ovarian cancer (搜索) is my career mission," said Memarzadeh. "When I see these results, I know we're getting closer to offering patients like mine a more effective and permanent solution."
The research was supported by the California Institute for Regenerative Medicine, the U.S. Department of Defense, the UCLA Broad Stem Cell Research Center (搜索), and multiple other institutional funding sources.